Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.22
JAZZ's Cash-to-Debt is ranked lower than
94% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. JAZZ: 0.22 )
Ranked among companies with meaningful Cash-to-Debt only.
JAZZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.83 Max: No Debt
Current: 0.22
Equity-to-Asset 0.41
JAZZ's Equity-to-Asset is ranked lower than
79% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. JAZZ: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
JAZZ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.84  Med: 0.4 Max: 0.87
Current: 0.41
-0.84
0.87
Interest Coverage 8.84
JAZZ's Interest Coverage is ranked lower than
86% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. JAZZ: 8.84 )
Ranked among companies with meaningful Interest Coverage only.
JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 9.24 Max: 76.32
Current: 8.84
0.7
76.32
Piotroski F-Score: 7
Altman Z-Score: 2.90
Beneish M-Score: -2.45
WACC vs ROIC
8.92%
16.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 39.70
JAZZ's Operating Margin % is ranked higher than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. JAZZ: 39.70 )
Ranked among companies with meaningful Operating Margin % only.
JAZZ' s Operating Margin % Range Over the Past 10 Years
Min: -252.34  Med: 33.51 Max: 46.95
Current: 39.7
-252.34
46.95
Net Margin % 26.78
JAZZ's Net Margin % is ranked higher than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. JAZZ: 26.78 )
Ranked among companies with meaningful Net Margin % only.
JAZZ' s Net Margin % Range Over the Past 10 Years
Min: -273.04  Med: 21.83 Max: 49.25
Current: 26.78
-273.04
49.25
ROE % 23.05
JAZZ's ROE % is ranked higher than
94% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. JAZZ: 23.05 )
Ranked among companies with meaningful ROE % only.
JAZZ' s ROE % Range Over the Past 10 Years
Min: 4.38  Med: 22.51 Max: 111.92
Current: 23.05
4.38
111.92
ROA % 9.50
JAZZ's ROA % is ranked higher than
91% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. JAZZ: 9.50 )
Ranked among companies with meaningful ROA % only.
JAZZ' s ROA % Range Over the Past 10 Years
Min: -113.42  Med: 9.82 Max: 64.21
Current: 9.5
-113.42
64.21
ROC (Joel Greenblatt) % 275.91
JAZZ's ROC (Joel Greenblatt) % is ranked higher than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. JAZZ: 275.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JAZZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5278.54  Med: 596.21 Max: 11377.93
Current: 275.91
-5278.54
11377.93
3-Year Revenue Growth Rate 19.30
JAZZ's 3-Year Revenue Growth Rate is ranked higher than
71% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. JAZZ: 19.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JAZZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 29.2 Max: 47.7
Current: 19.3
-2.3
47.7
3-Year EBITDA Growth Rate 18.40
JAZZ's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. JAZZ: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JAZZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 25.65 Max: 75.7
Current: 18.4
3.8
75.7
3-Year EPS without NRI Growth Rate 22.20
JAZZ's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. JAZZ: 22.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JAZZ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.4  Med: 5.4 Max: 61.7
Current: 22.2
-66.4
61.7
GuruFocus has detected 5 Warning Signs with Jazz Pharmaceuticals PLC $JAZZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JAZZ's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

JAZZ Guru Trades in Q2 2016

George Soros 7,800 sh (New)
Andreas Halvorsen 618,862 sh (New)
Jim Simons 719,508 sh (+234.50%)
Steven Cohen 218,900 sh (+193.83%)
Paul Tudor Jones 26,549 sh (+95.90%)
Pioneer Investments 472,089 sh (+2.08%)
Ken Fisher 1,859 sh (-4.62%)
Lee Ainslie 8,210 sh (-9.48%)
RS Investment Management 313,728 sh (-11.96%)
Joel Greenblatt 105,404 sh (-46.66%)
» More
Q3 2016

JAZZ Guru Trades in Q3 2016

Steven Cohen 352,200 sh (+60.90%)
Joel Greenblatt 153,251 sh (+45.39%)
Pioneer Investments 643,783 sh (+36.37%)
Jim Simons 914,800 sh (+27.14%)
Andreas Halvorsen 737,623 sh (+19.19%)
Lee Ainslie 9,710 sh (+18.27%)
Ken Fisher 2,006 sh (+7.91%)
George Soros Sold Out
Paul Tudor Jones 18,157 sh (-31.61%)
» More
Q4 2016

JAZZ Guru Trades in Q4 2016

Jim Simons 1,560,300 sh (+70.56%)
Pioneer Investments 822,687 sh (+27.79%)
Lee Ainslie 12,240 sh (+26.06%)
Andreas Halvorsen Sold Out
Ken Fisher 1,896 sh (-5.48%)
Steven Cohen 243,100 sh (-30.98%)
Joel Greenblatt 81,417 sh (-46.87%)
Paul Tudor Jones 8,109 sh (-55.34%)
» More
Q1 2017

JAZZ Guru Trades in Q1 2017

Andreas Halvorsen 197,830 sh (New)
Steven Cohen 376,904 sh (+55.04%)
Ken Fisher 1,896 sh (unchged)
Pioneer Investments 708,876 sh (-13.83%)
Lee Ainslie 10,180 sh (-16.83%)
Jim Simons 1,160,963 sh (-25.59%)
Paul Tudor Jones 2,386 sh (-70.58%)
Joel Greenblatt 12,616 sh (-84.50%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:EXEL, NAS:UTHR, NAS:IONS, OTCPK:GMXAY, OTCPK:NVZMF, NAS:NBIX, NAS:GLPG, NAS:TECH, NAS:KITE, NAS:ACAD, NAS:BLUE, OTCPK:BTGGF, NAS:CBPO, NAS:NKTR, NYSE:XON » details
Traded in other countries:J7Z.Germany,
Headquarter Location:Ireland
Jazz Pharmaceuticals PLC is a biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

Jazz Pharmaceuticals is an Ireland-based specialty pharmaceutical firm focused primarily on treatments for orphan indications. Jazz's product portfolio includes Xyrem for narcolepsy and Erwinaze for acute lymphoblastic leukemia.

Ratios

vs
industry
vs
history
PE Ratio 22.63
JAZZ's PE Ratio is ranked higher than
60% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. JAZZ: 22.63 )
Ranked among companies with meaningful PE Ratio only.
JAZZ' s PE Ratio Range Over the Past 10 Years
Min: 10.62  Med: 25.2 Max: 99999999.99
Current: 22.63
10.62
99999999.99
Forward PE Ratio 13.55
JAZZ's Forward PE Ratio is ranked higher than
74% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. JAZZ: 13.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.63
JAZZ's PE Ratio without NRI is ranked higher than
61% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. JAZZ: 22.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
JAZZ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.75  Med: 25.1 Max: 99999999.99
Current: 22.63
11.75
99999999.99
Price-to-Owner-Earnings 24.16
JAZZ's Price-to-Owner-Earnings is ranked higher than
57% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. JAZZ: 24.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JAZZ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.91  Med: 25.62 Max: 432.91
Current: 24.16
8.91
432.91
PB Ratio 4.53
JAZZ's PB Ratio is ranked lower than
59% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. JAZZ: 4.53 )
Ranked among companies with meaningful PB Ratio only.
JAZZ' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.41 Max: 32
Current: 4.53
2.46
32
PS Ratio 6.01
JAZZ's PS Ratio is ranked higher than
66% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. JAZZ: 6.01 )
Ranked among companies with meaningful PS Ratio only.
JAZZ' s PS Ratio Range Over the Past 10 Years
Min: 0.22  Med: 5.81 Max: 12
Current: 6.01
0.22
12
Price-to-Free-Cash-Flow 21.26
JAZZ's Price-to-Free-Cash-Flow is ranked higher than
57% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. JAZZ: 21.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JAZZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.82  Med: 18.38 Max: 91.14
Current: 21.26
11.82
91.14
Price-to-Operating-Cash-Flow 15.20
JAZZ's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. JAZZ: 15.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JAZZ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.61  Med: 16.03 Max: 55.81
Current: 15.2
9.61
55.81
EV-to-EBIT 17.27
JAZZ's EV-to-EBIT is ranked higher than
52% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. JAZZ: 17.27 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.5  Med: 16.6 Max: 74.1
Current: 17.27
-8.5
74.1
EV-to-EBITDA 14.47
JAZZ's EV-to-EBITDA is ranked higher than
56% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. JAZZ: 14.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 13.6 Max: 42.2
Current: 14.47
-10.9
42.2
PEG Ratio 0.99
JAZZ's PEG Ratio is ranked higher than
82% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. JAZZ: 0.99 )
Ranked among companies with meaningful PEG Ratio only.
JAZZ' s PEG Ratio Range Over the Past 10 Years
Min: 0.54  Med: 0.83 Max: 8.83
Current: 0.99
0.54
8.83
Shiller PE Ratio 305.11
JAZZ's Shiller PE Ratio is ranked lower than
96% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. JAZZ: 305.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
JAZZ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 208.78  Med: 536.53 Max: 978.38
Current: 305.11
208.78
978.38
Current Ratio 1.92
JAZZ's Current Ratio is ranked lower than
62% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. JAZZ: 1.92 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 2.76 Max: 5.55
Current: 1.92
0.2
5.55
Quick Ratio 1.82
JAZZ's Quick Ratio is ranked lower than
61% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. JAZZ: 1.82 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.59 Max: 5.46
Current: 1.82
0.17
5.46
Days Inventory 111.00
JAZZ's Days Inventory is ranked higher than
62% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. JAZZ: 111.00 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 95.63 Max: 146.18
Current: 111
70.82
146.18
Days Sales Outstanding 58.05
JAZZ's Days Sales Outstanding is ranked higher than
52% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. JAZZ: 58.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.12  Med: 46.7 Max: 58.05
Current: 58.05
30.12
58.05
Days Payable 99.41
JAZZ's Days Payable is ranked higher than
58% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. JAZZ: 99.41 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 73.94  Med: 79.92 Max: 150.36
Current: 99.41
73.94
150.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
JAZZ's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. JAZZ: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JAZZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.4  Med: -13.8 Max: -1.1
Current: -1.1
-32.4
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.47
JAZZ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. JAZZ: 1.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JAZZ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.17  Med: 2.93 Max: 68.98
Current: 1.47
1.17
68.98
Price-to-Median-PS-Value 1.05
JAZZ's Price-to-Median-PS-Value is ranked lower than
55% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. JAZZ: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JAZZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.95 Max: 1.58
Current: 1.05
0.05
1.58
Price-to-Peter-Lynch-Fair-Value 1.16
JAZZ's Price-to-Peter-Lynch-Fair-Value is ranked higher than
76% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. JAZZ: 1.16 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JAZZ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.08 Max: 14.94
Current: 1.16
0.68
14.94
Earnings Yield (Greenblatt) % 5.79
JAZZ's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. JAZZ: 5.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JAZZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 5.7 Max: 10.7
Current: 5.79
1.3
10.7
Forward Rate of Return (Yacktman) % 31.62
JAZZ's Forward Rate of Return (Yacktman) % is ranked higher than
77% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. JAZZ: 31.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JAZZ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -43.1  Med: 1.7 Max: 49.5
Current: 31.62
-43.1
49.5

More Statistics

Revenue (TTM) (Mil) $1,528
EPS (TTM) $ 6.63
Beta1.52
Short Percentage of Float3.06%
52-Week Range $95.80 - 163.75
Shares Outstanding (Mil)60.03

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,649 1,888 2,154
EPS ($) 10.69 12.83 15.39
EPS without NRI ($) 10.69 12.83 15.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.05%
Dividends per Share ($)
» More Articles for JAZZ

Headlines

Articles On GuruFocus.com
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences May 16 2017 
Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcole Apr 26 2017 
Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 Apr 25 2017 
Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatr Apr 24 2017 
Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigatio Apr 05 2017 
Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), a Apr 03 2017 
Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Comme Mar 31 2017 
Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma Feb 13 2017 
Actinium Pharmaceuticals Is Better Than Celator Feb 07 2017 
9 Stocks Trading Below the Peter Lynch Value Jan 11 2017 

More From Other Websites
ETFs with exposure to Jazz Pharmaceuticals Plc : May 22, 2017 May 22 2017
3 Value Stocks for Ambitious Investors May 21 2017
Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : May 18,... May 18 2017
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences May 16 2017
Edited Transcript of JAZZ earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017
4 of the Cheapest Biotech Stocks in the World May 10 2017
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales May 10 2017
Jazz misses Street 1Q forecasts May 09 2017
Jazz Pharma Reports Lagging First-Quarter Sales, Profits May 09 2017
Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results May 09 2017
Investor Network: Jazz Pharmaceuticals Plc to Host Earnings Call May 09 2017
Allergan's Q1 Sales Expected To Slip As Jazz Pharma Outperforms May 08 2017
4 Medical Stocks That Could Be Big Winners Next Week May 05 2017
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint? May 03 2017
3 Top Biotech Stocks to Buy Now Apr 29 2017
Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in... Apr 26 2017
Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 Apr 25 2017
Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in... Apr 24 2017
Jazz Pharmaceuticals, Inc. -- Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from... Apr 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat